-
ProductsOur company can produce anti-tumor, anti-fungal, antibiotics, nutrition, anesthesia, cardiovascular and cerebrovascular products such as 6 categories of series of products, the company's existing domestic products 73 product specifications and foreign products 22 product specifications.
-
NewsFrom 2019 to now, the company has attracted 38 kinds of generic drugs developed by 12 scientific research institutes such as Beijing Tongrentang Pharmaceutical Technology Development Co., Ltd. and Shanghai Rongdi Biotechnology Co., Ltd. to land in our company. After all of them are put into production, the annual output value can be increased by 1 billion and the profit can be about 0.2 billion.
Five APIs such as glycyrrhizic acid monopotassium salt were transferred to our company, and the API production line will be launched soon.
Date:
2017-03-21
After hard work, we have transferred 5 approval numbers of raw materials such as glycyrrhizic acid monopotassium salt from a pharmaceutical co., ltd. in Jiangsu province to our company. Due to the remarkable curative effect, high added value and broad prospects of these products, Hainan Yuyang Health Industry Co., Ltd. will invest 0.15 billion yuan to cooperate with our company to build a new API production line with an annual production scale. After the completion of the project, the annual output value of 0.138 billion yuan. For a long time, there has been a shortage of raw materials in the international market. 40% of the annual output of the five products is exported, earning 8.5 million US dollars. The project is expected to be put into production in early 2018 and has a very good market.
2017-03-21
After hard work, we have transferred 5 approval numbers of raw materials such as glycyrrhizic acid monopotassium salt from a pharmaceutical co., ltd. in Jiangsu province to our company.
Due to the remarkable curative effect, high added value and broad prospects of these products, Hainan Yuyang Health Industry Co., Ltd. will invest 0.15 billion yuan to cooperate with our company to build a new API production line with an annual production scale. After the completion of the project, the annual output value of 0.138 billion yuan.
For a long time, there has been a shortage of raw materials in the international market. 40% of the annual output of the five products is exported, earning 8.5 million US dollars. The project is expected to be put into production in early 2018 and has very good market prospects and economic benefits.
Key words:
Biopharmaceuticals
2023-07-02
Self-monitoring programme in 2023
2023-06-26
Fuze the world, a promise will be made!
Norcheng Pharmaceuticals
Copyright©2023 Shanxi Nuocheng Pharmaceutical Co., Ltd.